U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14ClFN8
Molecular Weight 348.7664
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-1480

SMILES

Cc1cc(=Nc2c(cnc(N[C@@]([H])(C)c3ncc(cn3)F)n2)Cl)[nH][nH]1

InChI

InChIKey=PDOQBOJDRPLBQU-QMMMGPOBSA-N
InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1

HIDE SMILES / InChI

Molecular Formula C14H14ClFN8
Molecular Weight 348.7664
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/9ae10fb573b7027df2bd5f4bfb02af75.html http://adisinsight.springer.com/drugs/800030336

AZD-1480 was being developed by AstraZeneca for the treatment of myeloproliferative disorders and solid tumours. AZD-1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. AZD-1480 had been in phase I clinical trials by AstraZeneca for the treatment of hepatocellular carcinoma and myelofibrosis. However, this study has been terminated for the safety and efficacy reasons in 2012.

CNS Activity

Curator's Comment:: In rats, AZD-1480 had good blood-brain barrier penetration

Approval Year

AUC

AUC

ValueDoseCo-administeredAnalytePopulation
57.6 μM × h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZD-1480 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZD-1480 plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Thirty-eight patients with advanced malignancies were treated at doses of 10–70mgonce daily (QD) and 20–45 mg b.i.d. .
Route of Administration: Oral
LN-17 cells were treated for 24 h with AZD1480 (0.05-1mkM) to determine whether Jak2 blockade can abrogate IL-6 dependent survival. Dose-dependent inhibition of pStat3Tyr705 and Stat3 DNA binding activity was observed in response to the addition of AZD1480, as was a loss of viability.
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:02:15 UTC 2021
Edited
by admin
on Sat Jun 26 06:02:15 UTC 2021
Record UNII
KL2Z2TLF01
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-1480
Common Name English
AZD1480
Code English
2,4-PYRIMIDINEDIAMINE, 5-CHLORO-N2-((1S)-1-(5-FLUORO-2-PYRIMIDINYL)ETHYL)-N4-(5-METHYL-1H-PYRAZOL-3-YL)-
Systematic Name English
AZD 1480 [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
KL2Z2TLF01
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
DRUG BANK
DB12588
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL1231124
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
PUBCHEM
16659841
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
EPA CompTox
935666-88-9
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
CAS
935666-88-9
Created by admin on Sat Jun 26 06:02:15 UTC 2021 , Edited by admin on Sat Jun 26 06:02:15 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY